International Immune Tolerance Study

The purpose of this study is to see if a low-dose arm or a high dose-arm of immune tolerance is more effective in eliminating inhibitors in patients with hemophilia A.

Lead sponsor: New York Presbyterian Hospital•39 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

COMPLETEDPhase 2/3

Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors

NCT00221195 · Hemophilia A With Inhibitors

UNKNOWNPhase 2

rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors

NCT01105546 · Hemophilia A With Inhibitors

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 7, 2009Terms

Trial snapshot

StatusTERMINATED

PhaseNA

Enrollment134

Start dateJul 2002

Last updatedDec 7, 2009

Condition

Hemophilia A With Inhibitors

Locations shown

University of Alabama Birmingham Medical Center

Birmingham, Alabama

City of Hope Medical Center

Duarte, California

Children's Hospital of Orange County

Orange, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 7, 2009Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions